# US 2010/0137377 A1 · Novel compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0137377 A1
- Document ID: US20100137377A1
- Status: Published application
- Kind: A1
- Application number: 12/595,310
- Filed: 2008-04-09
- Published: 2010-06-03
- Earliest claimed: 2007-04-11
- Assignees: Soren Ebdrup Et Al
- Inventors: Anders Klarskov Petersen; Soren Ebdrup
- Web page: https://patentgrep.com/patent/US20100137377A1

## CPC

- A01N 43/40: six-membered rings
- A01N 37/40: having at least one carboxylic group or a thio analogue, or a derivative thereof, and one oxygen or sulfur atom attached to the same aromatic ring system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/14: for baldness or alopecia
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/10: for petit-mal
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 27/02: Ophthalmic agents
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 235/54: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07D 213/643: 2-Phenoxypyridines; Derivatives thereof
- C07C 2603/74: Adamantanes
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.

## Claims

### Claim 1

A compound of the general formula (I):
wherein R1 is selected from the group consisting of:
wherein the symbol * denotes the point of attachment,
R2 is selected from the group consisting of phenyl substituted with one or two independently selected R3 and pyridinyl substituted with one or two independently selected R3;
R3 is selected from the group consisting of halogen, cyano, —C(═O)OH, —C(═O)R4, —CH(OH)R4, C(═O)—NR6R7, —OR4, —SR4, —S(═O)2R4, —S(═O)2—NR6R7, —C═CR4R5, —C≡C—R4R5, —C3-C10heterocyclyl optionally substituted with halogen or methyl, C3-C10cycloalkyl optionally substituted with halogen, methyl or hydroxy, phenyl optionally substituted with —C(═O)OH, halogen or methyl, C1-C6alkyl optionally substituted with R4 and heteroaryl optionally substituted with —C(═O)OH, halogen or methyl;
R4 is selected from the group consisting of hydrogen, C1-C6alkyl, phenyl, heteroaryl and C3-C10cycloalkyl, wherein said C1-C6alkyl, phenyl, heteroaryl and C3-C10cycloalkyl are optionally substituted with —C(═O)OH, —CH2OH, halogen, methyl, trifluoromethyl, methoxy or hydroxyl and —C(═O)NH2;
R5 is selected from the group consisting of hydrogen, C1-C6alkyl, phenyl, heteroaryl and C3-C10cycloalkyl, wherein said C1-C6alkyl, phenyl, heteroaryl and C3-C10cycloalkyl are optionally substituted with —C(═O)OH, —CH2OH, halogen, methyl, trifluoromethyl, methoxy or hydroxy;
R6 is selected from the group consisting of hydrogen, C1-C6alkyl, tetrahydropyranyl and C3-C10cycloalkyl, wherein said C1-C6alkyl, tetrahydropyranyl, and C3-C10cycloalkyl are optionally substituted with one or two substituents independently selected from the group consisting of halogen and hydroxy;
R7 is selected from the group consisting of hydrogen, C1-C6alkyl, tetrahydropyranyl and C3-C10cycloalkyl, wherein said C1-C6alkyl, tetrahydropyranyl, and C3-C10cycloalkyl are optionally substituted with one or two substituents independently selected from the group consisting of halogen and hydroxy;
or R6 and R7 together with the nitrogen atom to which they are attached form a piperidine or a pyrrolidine ring, wherein said ring is optionally substituted with hydroxy or halogen;
or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.

### Claim 2

A compound of the general formula (I):
wherein R1 is selected from the group consisting of:
wherein the symbol * denotes the point of attachment,
R2 is selected from the group consisting of phenyl substituted with one or two independently selected R3 and pyridinyl substituted with one or two independently selected R3;
R3 is selected from the group consisting of halogen, cyano, —C(═O)OH, —C(═O)R4, —CH(OH)R4, C(═O)—NR6R7, —OR4, —SR4, —S(═O)2R4, —S(═O)2—NR6R7, —C═CR4R5, —C≡C—R4R5, —C3-C10heterocyclyl optionally substituted with halogen or methyl, C3-C10cycloalkyl optionally substituted with halogen, methyl or hydroxy, phenyl optionally substituted with —C(═O)OH, halogen or methyl, C1-C6alkyl optionally substituted with R4 and heteroaryl optionally substituted with —C(═O)OH, halogen or methyl;
R4 is selected from the group consisting of hydrogen, C1-C6alkyl, phenyl, heteroaryl and C3-C10cycloalkyl, wherein said C1-C6alkyl, phenyl, heteroaryl and C3-C10cycloalkyl are optionally substituted with —C(═O)OH, —CH2OH, halogen, methyl, trifluoromethyl, methoxy or hydroxyl and —C(═O)NH2;
R5 is selected from the group consisting of hydrogen, C1-C6alkyl, phenyl, heteroaryl and C3-C10cycloalkyl, wherein said C1-C6alkyl, phenyl, heteroaryl and C3-C10cycloalkyl are optionally substituted with —C(═O)OH, —CH2OH, halogen, methyl, trifluoromethyl, methoxy or hydroxy;
R6 is selected from the group consisting of hydrogen, C1-C6alkyl, tetrahydropyranyl and C3-C10cycloalkyl, wherein said C1-C6alkyl, tetrahydropyranyl, and C3-C10cycloalkyl are optionally substituted with one or two substituents independently selected from the group consisting of halogen and hydroxy;
R2 is selected from the group consisting of hydrogen, C1-C6alkyl, tetrahydropyranyl and C3-C10cycloalkyl, wherein said C1-C6alkyl, tetrahydropyranyl, and C3-C10cycloalkyl are optionally substituted with one or two substituents independently selected from the group consisting of halogen and hydroxy;
or R6 and R7 together with the nitrogen atom to which they are attached form a piperidine or a pyrrolidine ring, wherein said ring is optionally substituted with hydroxy or halogen;
or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein R1 is

### Claim 4 (depends on 1)

The compound according to claim 1, wherein R1 is

### Claim 5 (depends on 1)

The compound according to claim 1, wherein R1 is

### Claim 6 (depends on 1)

The compound according to claim 1, wherein R1 is

### Claim 7 (depends on 1)

The compound according to claim 1, wherein R2 is phenyl substituted with one or two independently selected R3.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein R2 is pyridinyl substituted with one or two independently selected R3.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein R3 is selected from the group consisting of cyano and halogen.

### Claim 10

A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of 4-(2,4-Dichloro-phenoxy)-N-(5-hydroxy-adamantan-2-yl)-benzamide, 4-(5-Cyano-pyridin-2-yloxy)-N-(5-hydroxy-adamantan-2-yl)-benzamide, 4-(5-Chloro-pyridin-2-yloxy)-N-(5-hydroxy-adamantan-2-yl)-benzamide, 4-(5-Chloro-pyridin-2-yloxy)-N-(5-hydroxymethyl-adamantan-2-yl)-benzamide, and 4-(5-Chloro-pyridin-2-yloxy)-N-(4-hydroxymethyl-cyclohexyl)-N-methyl-benzamide.

### Claim at position 11

11-15. (canceled)

### Claim 16 (depends on 1)

A pharmaceutical composition comprising, as an active ingredient, at least one compound according to claim 1 together with one or more pharmaceutically acceptable carriers or excipients.

### Claim 17 (depends on 1)

A method for the treatment, prevention and/or prophylaxis of any conditions, disorders or diseases wherein a modulation or an inhibition of the activity of 11βHSD1 is beneficial, the method comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.

### Claim 18 (depends on 17)

The method according to claim 17 wherein the conditions, disorders or diseases are selected from the group consisting of the metabolic syndrome, insulin resistance, dyslipidemia, hypertension and obesity.

### Claim 19 (depends on 17)

The method according to claim 17, wherein the conditions, disorders or diseases are selected from the group consisting of type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG).

### Claim 20 (depends on 17)

The method according to claim 17, wherein the conditions, disorders or diseases are selected from the group consisting of conditions, disorders and diseases that are influenced by intracellular glucocorticoid levels.

### Claim 21 (depends on 17)

The method according to claim 17, wherein the conditions, disorders or diseases are due to the adverse effects of glucocorticoid receptor agonist treatment or therapy.
